Retrophin Inc. (Nasdaq: RTRX) will acquire the worldwide rights to the first Food and
Drug Adminstration approved pediatric and adult patients with bile acid
synthesis disorders treatment Cholban sending the stock price soaring $5.441 to close at $20.17.
Retrophin to acquire worldwide rights to Cholban
March 18, 2015 at 19:11 PM EDT
